Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milena Cannella

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Scientific Reports|September 8, 2018
mGlu1 Receptors Monopolize the Synaptic Control of Cerebellar Purkinje Cells by Epigenetically Down-Regulating mGlu5 ReceptorsSerena Notartomaso, Harumi Nakao, Giada Mascio, et al.
Journal of Cellular and Molecular Medicine|January 20, 2010
Early defect of transforming growth factor β1 formation in Huntington's diseaseGiuseppe Battaglia, Milena Cannella, Barbara Riozzi, et al.
Brain : a Journal of Neurology|March 5, 2003
Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical courseFerdinando Squitieri, Cinzia Gellera, Milena Cannella, et al.
Epilepsia|September 16, 2017
Alterations in the α<sub>2</sub> δ ligand, thrombospondin-1, in a rat model of spontaneous absence epilepsy and in patients with idiopathic/genetic generalized epilepsiesInes Santolini, Roberta Celli, Milena Cannella, et al.
Current Neuropharmacology|May 17, 2022
mGlu3 Metabotropic Glutamate Receptors as a Target for the Treatment of Absence Epilepsy: Preclinical and Human Genetics DataRoberta Celli, Pasquale Striano, Rita Citraro, et al.
Elife|August 22, 2024
A 'double-edged' role for type-5 metabotropic glutamate receptors in pain disclosed by light-sensitive drugsSerena Notartomaso, Nico Antenucci, Mariacristina Mazzitelli, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
A "double-edged" role for type-5 metabotropic glutamate receptors in pain disclosed by light-sensitive drugsSerena Notartomaso, Nico Antenucci, Mariacristina Mazzitelli, et al.
Molecular Pharmacology|December 17, 2010
Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotectiveFilippo Caraci, Gemma Molinaro, Giuseppe Battaglia, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 1, 2019
Developmental abnormalities in cortical GABAergic system in mice lacking mGlu3 metabotropic glutamate receptorsTiziana Imbriglio, Remy Verhaeghe, Katiuscia Martinello, et al.
American Journal of Human Genetics|November 19, 2003
Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformationsChristina L Liquori, Michel J Berg, Adrian M Siegel, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Scientific Reports|September 8, 2018
mGlu1 Receptors Monopolize the Synaptic Control of Cerebellar Purkinje Cells by Epigenetically Down-Regulating mGlu5 ReceptorsSerena Notartomaso, Harumi Nakao, Giada Mascio, et al.
Journal of Cellular and Molecular Medicine|January 20, 2010
Early defect of transforming growth factor β1 formation in Huntington's diseaseGiuseppe Battaglia, Milena Cannella, Barbara Riozzi, et al.
Brain : a Journal of Neurology|March 5, 2003
Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical courseFerdinando Squitieri, Cinzia Gellera, Milena Cannella, et al.
Epilepsia|September 16, 2017
Alterations in the α<sub>2</sub> δ ligand, thrombospondin-1, in a rat model of spontaneous absence epilepsy and in patients with idiopathic/genetic generalized epilepsiesInes Santolini, Roberta Celli, Milena Cannella, et al.
Current Neuropharmacology|May 17, 2022
mGlu3 Metabotropic Glutamate Receptors as a Target for the Treatment of Absence Epilepsy: Preclinical and Human Genetics DataRoberta Celli, Pasquale Striano, Rita Citraro, et al.
Elife|August 22, 2024
A 'double-edged' role for type-5 metabotropic glutamate receptors in pain disclosed by light-sensitive drugsSerena Notartomaso, Nico Antenucci, Mariacristina Mazzitelli, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
A "double-edged" role for type-5 metabotropic glutamate receptors in pain disclosed by light-sensitive drugsSerena Notartomaso, Nico Antenucci, Mariacristina Mazzitelli, et al.
Molecular Pharmacology|December 17, 2010
Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotectiveFilippo Caraci, Gemma Molinaro, Giuseppe Battaglia, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 1, 2019
Developmental abnormalities in cortical GABAergic system in mice lacking mGlu3 metabotropic glutamate receptorsTiziana Imbriglio, Remy Verhaeghe, Katiuscia Martinello, et al.
American Journal of Human Genetics|November 19, 2003
Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformationsChristina L Liquori, Michel J Berg, Adrian M Siegel, et al.
Pageof 6